John Zalcberg, PhD, medical oncologist, Peter MacCallum Cancer Centre, Melbourne, Australia, talks about the poor prognosis of refractory advanced oesophago-gastric cancer (AOGC) patients and how regorafenib could benefit those patients.
John Zalcberg, PhD, medical oncologist, Peter MacCallum Cancer Centre, Melbourne, Australia, talks about the poor prognosis of refractory advanced oesophago-gastric cancer (AOGC) patients and how regorafenib could benefit those patients.
Zalcberg says average survival is usually between 12 and 14 months, although a randomized phase II study of regorafenib in AOGC patients has shown improved progression-free survival. Zalcberg and his team of medical professionals examined Caucasian patients from Australia, New Zealand, and Canada compared to patients from Korea.
Zalcberg says he hopes to enter a phase III trial study to prove the benefits of regorafenib in the near future.
The Impact of the Gut Microbiome in Young Patients With Colorectal Cancer
February 15th 2021In season 2, episode 2 of Targeted Talks, Cathy Eng, MD, speaks with Benjamin Weinberg, MD, about the gut microbiome, and how the presence of certain microbiota impact the onset and intensity of disease as well as the potential response to certain treatments.
Listen